Pub Date : 2019-09-28DOI: 10.1183/13993003.congress-2019.pa3642
D. J. Castro, A. Quezada, J. Lobo, R. Morillo, E. Barbero, D. Chiluiza, E. Mercedes, F. León, D. Barrios, R. Yusen
{"title":"Assessment of myocardial injury in low-risk acute pulmonary embolism","authors":"D. J. Castro, A. Quezada, J. Lobo, R. Morillo, E. Barbero, D. Chiluiza, E. Mercedes, F. León, D. Barrios, R. Yusen","doi":"10.1183/13993003.congress-2019.pa3642","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa3642","url":null,"abstract":"","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73791628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-28DOI: 10.1183/13993003.congress-2019.pa1460
L. Jara-Palomares, S. Marin-Romero, M. Asensio-Cruz, T. Elías-Hernández, Rocío Ortega-Rivera, R. Otero-Candelera, E. Montero-Romero, Rodrigo Tallon-Aguilar, Maria Dolores Ucero-Leon, Manuel Arellano-Ceballos, M. Espada, C. Fernandez-Garcia, J. Sánchez-Díaz, V. Sánchez-López, E. Arellano-Orden, M. Ferrer-Galván, Stefano Barco
{"title":"Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin","authors":"L. Jara-Palomares, S. Marin-Romero, M. Asensio-Cruz, T. Elías-Hernández, Rocío Ortega-Rivera, R. Otero-Candelera, E. Montero-Romero, Rodrigo Tallon-Aguilar, Maria Dolores Ucero-Leon, Manuel Arellano-Ceballos, M. Espada, C. Fernandez-Garcia, J. Sánchez-Díaz, V. Sánchez-López, E. Arellano-Orden, M. Ferrer-Galván, Stefano Barco","doi":"10.1183/13993003.congress-2019.pa1460","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa1460","url":null,"abstract":"","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78793441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-28DOI: 10.1183/13993003.congress-2019.pa1458
P. R. G. Torres, Claudio Villaquiran Torres, C. Preciado, A. Arboleda, Javier Ivan Lasso Apraez
Pulmonary thromboembolism (PE) causes high morbidity and mortality. Due to limited information about the disease in our country, information from others must often be used. That is why we conducted a prospective observational study on the epidemiology of PE treated in a high complexity hospital from Colombia. A search of the scientific literature was carried out finding several initiatives and only two previous local ones. A review of the risk factors, clinical presentation, diagnostic process, treatment, complications and prognosis of the disease was used to construct the tool for data collection in the RedCap program. Between November 2017 and 2018, 122 reports were obtained and after the review, 113 patients were included. A diagnosis of PE was obtained every 3.2 days, being a pathology that mainly affects women older than 60 years. The most frequent risk factors were cancer, limitation for mobilization and history of deep vein thrombosis (DVT). The most frequent symptoms were dyspnea, chest pain and cough. DVT was present in a third of the cases, being mostly distal. The diagnostic methods most used in our hospital are those described in the literature. In spite that a quarter of the patients had dysfunction of the right ventricle, mortality was only 3.5%. When classifying the risk according to PESI, most patients had intermediate risk. This score had a better performance than the shock index for stratifying patients with a high risk of mortality. No relationship was found between biomarkers or dysfunction of the right ventricle and mortality. A 10% of patients had a high risk of developing CTEPH. Our registry allows to know in a greater depth the characteristics of this pathology in a South American Hospital.
{"title":"Pulmonary Embolism Registry of a South American Hospital","authors":"P. R. G. Torres, Claudio Villaquiran Torres, C. Preciado, A. Arboleda, Javier Ivan Lasso Apraez","doi":"10.1183/13993003.congress-2019.pa1458","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa1458","url":null,"abstract":"Pulmonary thromboembolism (PE) causes high morbidity and mortality. Due to limited information about the disease in our country, information from others must often be used. That is why we conducted a prospective observational study on the epidemiology of PE treated in a high complexity hospital from Colombia. A search of the scientific literature was carried out finding several initiatives and only two previous local ones. A review of the risk factors, clinical presentation, diagnostic process, treatment, complications and prognosis of the disease was used to construct the tool for data collection in the RedCap program. Between November 2017 and 2018, 122 reports were obtained and after the review, 113 patients were included. A diagnosis of PE was obtained every 3.2 days, being a pathology that mainly affects women older than 60 years. The most frequent risk factors were cancer, limitation for mobilization and history of deep vein thrombosis (DVT). The most frequent symptoms were dyspnea, chest pain and cough. DVT was present in a third of the cases, being mostly distal. The diagnostic methods most used in our hospital are those described in the literature. In spite that a quarter of the patients had dysfunction of the right ventricle, mortality was only 3.5%. When classifying the risk according to PESI, most patients had intermediate risk. This score had a better performance than the shock index for stratifying patients with a high risk of mortality. No relationship was found between biomarkers or dysfunction of the right ventricle and mortality. A 10% of patients had a high risk of developing CTEPH. Our registry allows to know in a greater depth the characteristics of this pathology in a South American Hospital.","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87104069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-28DOI: 10.1183/13993003.congress-2019.pa3650
J. Hernández Borge, Luis Miguel Sierra Murillo, Kaoutar El Boutaibi Faiz, P. Cordero Montero, A. Castañar Jover, María Teresa Gómez Vizcaino, Amparo Sanz Cabrera, F. L. Márquez Pérez
Pulmonary thromboembolism (PTE) has important economic burden related, fundamentally, to the costs of hospital admission. Our objective were to analyze what factors can influence the hospital stay of patients with PTE. Retrospective cohort study of patients with PTE (January 2007 - May 2016). A descriptive and comparative analysis was performed according to the hospital stay and a multivariate analysis of the factors related to it. We included 430 patients (mean age: 63.7 ± 16.5 years, 55.3% men). Median hospital stay: 12 days (IQR: 3-80). In the univariate analysis the stay was longer in: Older patients, higher score of the PESI scale, Obese (BMI> 30), with surgery as a risk factor, with absence of previous PTE, presence of syncope, lower PaO2, higher levels of glycemia, presence of pahological EKG or thorax X-Ray (XR), severity in the affectation of angioCT, pathological echocardiography, appearance of hemorrhagic and non-hemorrhagic complications during admission, need for transfusion or admission to the ICU. Variables that were associated, independently, with a longer hospital stay were: age (OR: 1.01, 95% CI: 1-1.02), obesity (OR: 1.88: 95% CI: 1.12-3, 14), absence of previous PET (OR: 3.09, 95% CI: 1.17-8.16), PaO2 (OR: 0.98, 95% CI: 0.97-1), presence of pathological XR (OR: 1.49, 95% CI: 0.98-2.27), admission to the ICU (OR: 1.68, 95% CI: 1.03-2.73) and, presence of complications, both, haemorrhagic (OR: 2.20, 95% CI: 1.09-4.43) and non-haemorrhagic (OR: 2.80, 95% CI: 1.70-4.62), during hospitalization. In patients with PTE, several epidemiological characteristics, severity at presentation variables and, above all, evolution variables were associated with longer stays.
{"title":"Factors related to hospital stay of patients with pulmonary thromboembolism","authors":"J. Hernández Borge, Luis Miguel Sierra Murillo, Kaoutar El Boutaibi Faiz, P. Cordero Montero, A. Castañar Jover, María Teresa Gómez Vizcaino, Amparo Sanz Cabrera, F. L. Márquez Pérez","doi":"10.1183/13993003.congress-2019.pa3650","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa3650","url":null,"abstract":"Pulmonary thromboembolism (PTE) has important economic burden related, fundamentally, to the costs of hospital admission. Our objective were to analyze what factors can influence the hospital stay of patients with PTE. Retrospective cohort study of patients with PTE (January 2007 - May 2016). A descriptive and comparative analysis was performed according to the hospital stay and a multivariate analysis of the factors related to it. We included 430 patients (mean age: 63.7 ± 16.5 years, 55.3% men). Median hospital stay: 12 days (IQR: 3-80). In the univariate analysis the stay was longer in: Older patients, higher score of the PESI scale, Obese (BMI> 30), with surgery as a risk factor, with absence of previous PTE, presence of syncope, lower PaO2, higher levels of glycemia, presence of pahological EKG or thorax X-Ray (XR), severity in the affectation of angioCT, pathological echocardiography, appearance of hemorrhagic and non-hemorrhagic complications during admission, need for transfusion or admission to the ICU. Variables that were associated, independently, with a longer hospital stay were: age (OR: 1.01, 95% CI: 1-1.02), obesity (OR: 1.88: 95% CI: 1.12-3, 14), absence of previous PET (OR: 3.09, 95% CI: 1.17-8.16), PaO2 (OR: 0.98, 95% CI: 0.97-1), presence of pathological XR (OR: 1.49, 95% CI: 0.98-2.27), admission to the ICU (OR: 1.68, 95% CI: 1.03-2.73) and, presence of complications, both, haemorrhagic (OR: 2.20, 95% CI: 1.09-4.43) and non-haemorrhagic (OR: 2.80, 95% CI: 1.70-4.62), during hospitalization. In patients with PTE, several epidemiological characteristics, severity at presentation variables and, above all, evolution variables were associated with longer stays.","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88340521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-28DOI: 10.1183/13993003.congress-2019.pa1466
M. Prasad, Y. Uday
{"title":"Pulmonary thrombosis occurring in hypobaric hypoxia among previously healthy young adult males","authors":"M. Prasad, Y. Uday","doi":"10.1183/13993003.congress-2019.pa1466","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa1466","url":null,"abstract":"","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80802508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-28DOI: 10.1183/13993003.congress-2019.pa3654
Clara Vigneron, A. Vivot, M. Jamme, A. Gibelin, G. Briend, J. Pastre, B. Planquette, G. Meyer, O. Sanchez
Introduction: In randomized controlled trials, direct oral anticoagulants are at least as effective and probably safer than standard anticoagulation in patients with venous thromboembolism (VTE). Real-life studies are of particular interest for the assessment of their efficacy and safety in unselected patients. Methods: We conducted a retrospective analysis of a prospective monocentric cohort including patients with symptomatic pulmonary embolism (PE) treated with VKA or rivaroxaban (riva) with a 6-month follow-up. We distinguished 2 periods: P1 (2010-2013) when only VKA was available; P2 (2014-2017) when VKA and riva were available. The primary outcome was the composite of all-cause mortality, major or clinically significant bleeding and symptomatic recurrent VTE under treatment. Outcomes and length of stay (LOS) were compared between riva and VKA groups using a propensity score analysis. Results: 706 patients were analysed: 271 during P1, 435 during P2 (VKA: n=143, Riva: n=292). No difference in the primary outcome was observed between P1 and P2 (respectively 8,1% vs 4,8%, p=0.1045). LOS was significantly reduced during P2 (5 [3,7] vs 6 days [4,10], p During P2, compared to VKA, patients treated with riva were younger (65 [49,75] vs 71 years [53,82], p=0.0044) and the proportion of patients with comorbidities was lower. In the propensity score adjustment sample, the primary outcome (OR 2.91 [95%CI, 1.03-8.26], p=0.044) was significantly higher in the VKA group compared to the riva group. LOS was significantly reduced in the riva group (4 vs 7 days, p Conclusion: Riva appears to be effective and safe to treat PE in a non-selected population with a shorter LOS.
{"title":"Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study","authors":"Clara Vigneron, A. Vivot, M. Jamme, A. Gibelin, G. Briend, J. Pastre, B. Planquette, G. Meyer, O. Sanchez","doi":"10.1183/13993003.congress-2019.pa3654","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa3654","url":null,"abstract":"Introduction: In randomized controlled trials, direct oral anticoagulants are at least as effective and probably safer than standard anticoagulation in patients with venous thromboembolism (VTE). Real-life studies are of particular interest for the assessment of their efficacy and safety in unselected patients. Methods: We conducted a retrospective analysis of a prospective monocentric cohort including patients with symptomatic pulmonary embolism (PE) treated with VKA or rivaroxaban (riva) with a 6-month follow-up. We distinguished 2 periods: P1 (2010-2013) when only VKA was available; P2 (2014-2017) when VKA and riva were available. The primary outcome was the composite of all-cause mortality, major or clinically significant bleeding and symptomatic recurrent VTE under treatment. Outcomes and length of stay (LOS) were compared between riva and VKA groups using a propensity score analysis. Results: 706 patients were analysed: 271 during P1, 435 during P2 (VKA: n=143, Riva: n=292). No difference in the primary outcome was observed between P1 and P2 (respectively 8,1% vs 4,8%, p=0.1045). LOS was significantly reduced during P2 (5 [3,7] vs 6 days [4,10], p During P2, compared to VKA, patients treated with riva were younger (65 [49,75] vs 71 years [53,82], p=0.0044) and the proportion of patients with comorbidities was lower. In the propensity score adjustment sample, the primary outcome (OR 2.91 [95%CI, 1.03-8.26], p=0.044) was significantly higher in the VKA group compared to the riva group. LOS was significantly reduced in the riva group (4 vs 7 days, p Conclusion: Riva appears to be effective and safe to treat PE in a non-selected population with a shorter LOS.","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79869916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-28DOI: 10.1183/13993003.congress-2019.pa1469
Saleel Punnilath Abdulsamad, E. Crawford, A. Makan, N. Ahmad, K. Srinivasan, H. Moudgil
{"title":"Categorising sub-massive pulmonary thromboembolism: no isolated role for shock index or its modified form","authors":"Saleel Punnilath Abdulsamad, E. Crawford, A. Makan, N. Ahmad, K. Srinivasan, H. Moudgil","doi":"10.1183/13993003.congress-2019.pa1469","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa1469","url":null,"abstract":"","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86646846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-28DOI: 10.1183/13993003.congress-2019.pa1455
J. Heggie, Bilal Shoaib, M. Pagaria
{"title":"Adherence to standard diagnostic algorithms for pulmonary embolus in a UK district general hospital","authors":"J. Heggie, Bilal Shoaib, M. Pagaria","doi":"10.1183/13993003.congress-2019.pa1455","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa1455","url":null,"abstract":"","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76680323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-28DOI: 10.1183/13993003.congress-2019.pa3651
Esther Barbero Herranz, C. Coscia, Ana Jaureguizar, C. A. Quezada, A. Muriel, M. Monreal, T. Villén, D. Chiluiza, Joger Yusen, D. Jiménez
It is unknown whether the efficacy of treatments for venous thromboembolic disease (VTE) estimated by observational studies with propensity analysis is similar to the one estimated by clinical trials (ECs). A systematic review of PubMed and Web of Science was conducted to identify observational studies with propensity analysis that would have evaluated the effect of VTE treatments on short term all-cause mortality. After identifying the treatment scenarios evaluated by the observational studies, a standardized algorithm was used to match them with at least one CE or a meta-analysis of ECs. The efficacy of the treatment (relative odds ratio [OR]) between the observational studies and the paired Ecs was compared. The global relative OR for all clinical scenarios was also calculated. Results: observational studies and CSs evaluated 7 treatment scenarios for VTE. There was no statistically significant difference in the effect on mortality obtained by observational studies compared to CSs (OR 0.89 [95%CI,0.32-1.46]). However, in 2 scenarios (thrombolysis vs. anticoagulation for lung thromboembolism, treatment with enoxaparin once or twice a day for VTE) there were statistically significant differences in the direction of effect, and there were no significant differences in the magnitude of the effect in 2 other scenarios (rivaroxaban vs. vitamin K antagonists for the treatment of VTE, home treatment vs. hospitalization for deep vein thrombosis). Conclusions: observational studies that use propensity analysis and CSs find similar results regarding the effect of VTE treatments, although there are occasionally differences in the direction/magnitude of this effect.
目前尚不清楚通过倾向分析的观察性研究估计的治疗静脉血栓栓塞性疾病(VTE)的疗效是否与临床试验(ECs)估计的疗效相似。对PubMed和Web of Science进行了系统回顾，以确定观察性研究，并进行倾向分析，以评估静脉血栓栓塞治疗对短期全因死亡率的影响。在确定观察性研究评估的治疗方案后，使用标准化算法将其与至少一个CE或ec的荟萃分析相匹配。比较观察性研究和配对Ecs之间的治疗效果(相对优势比[OR])。还计算了所有临床情况的全局相对OR。结果:观察性研究和CSs评估了静脉血栓栓塞的7种治疗方案。与CSs相比，观察性研究对死亡率的影响无统计学差异(OR 0.89 [95%CI,0.32-1.46])。然而，在2种情况下(溶栓vs抗凝治疗肺血栓栓塞，静脉血栓栓塞用依诺肝素治疗1 - 2天)，效果的方向有统计学意义的差异，而在其他2种情况下(利伐沙班vs维生素K拮抗剂治疗静脉血栓，家庭治疗vs深静脉血栓住院治疗)，效果的大小没有显著差异。结论:使用倾向分析和CSs的观察性研究发现关于静脉血栓栓塞治疗效果的相似结果，尽管这种效果的方向/幅度偶尔存在差异。
{"title":"Effectiveness of the tromboembolic venous disease treatments estimated through clinical trials vs. observational studies","authors":"Esther Barbero Herranz, C. Coscia, Ana Jaureguizar, C. A. Quezada, A. Muriel, M. Monreal, T. Villén, D. Chiluiza, Joger Yusen, D. Jiménez","doi":"10.1183/13993003.congress-2019.pa3651","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa3651","url":null,"abstract":"It is unknown whether the efficacy of treatments for venous thromboembolic disease (VTE) estimated by observational studies with propensity analysis is similar to the one estimated by clinical trials (ECs). A systematic review of PubMed and Web of Science was conducted to identify observational studies with propensity analysis that would have evaluated the effect of VTE treatments on short term all-cause mortality. After identifying the treatment scenarios evaluated by the observational studies, a standardized algorithm was used to match them with at least one CE or a meta-analysis of ECs. The efficacy of the treatment (relative odds ratio [OR]) between the observational studies and the paired Ecs was compared. The global relative OR for all clinical scenarios was also calculated. Results: observational studies and CSs evaluated 7 treatment scenarios for VTE. There was no statistically significant difference in the effect on mortality obtained by observational studies compared to CSs (OR 0.89 [95%CI,0.32-1.46]). However, in 2 scenarios (thrombolysis vs. anticoagulation for lung thromboembolism, treatment with enoxaparin once or twice a day for VTE) there were statistically significant differences in the direction of effect, and there were no significant differences in the magnitude of the effect in 2 other scenarios (rivaroxaban vs. vitamin K antagonists for the treatment of VTE, home treatment vs. hospitalization for deep vein thrombosis). Conclusions: observational studies that use propensity analysis and CSs find similar results regarding the effect of VTE treatments, although there are occasionally differences in the direction/magnitude of this effect.","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84255071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-28DOI: 10.1183/13993003.congress-2019.pa3637
F. Couturaud, L. Bertoletti, O. Sanchez, R. Mao, P. Roy, F. Gagnadoux, N. Paleiron, Jeannot Schmidt, J. Pastre, E. Magalhaes, Y. Auffret, C. Hoffmann, L. Bressollette, M. Nonent, P. Salaun, P. Mismetti, P. Girard, K. Lacut, C. Lemarié, C. Tromeur, G. Meyer, C. Leroyer
{"title":"Late Breaking Abstract - Frequency Pulmonary embolism (PE) in patients with an acute Exacerbation of chronic obstructive Pulmonary disease (COPD). PEP prospective trial","authors":"F. Couturaud, L. Bertoletti, O. Sanchez, R. Mao, P. Roy, F. Gagnadoux, N. Paleiron, Jeannot Schmidt, J. Pastre, E. Magalhaes, Y. Auffret, C. Hoffmann, L. Bressollette, M. Nonent, P. Salaun, P. Mismetti, P. Girard, K. Lacut, C. Lemarié, C. Tromeur, G. Meyer, C. Leroyer","doi":"10.1183/13993003.congress-2019.pa3637","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa3637","url":null,"abstract":"","PeriodicalId":20797,"journal":{"name":"Pulmonary embolism","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75002899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：